

Public Trust Board Paper G

Meeting title:	Public Trust Board				
Date of the meeting:	10 August 2023				
Title:	Escalation Report: Operations and Performance Committee 26 July 2023 - Public				
Report presented by:	Mike Williams, Operations and Performance Committee, Non-Executive Director, Chair				
Report written by:	Alison Moss, Corporate and Committee Services Officer				
	Decision/Approval		Assurance	x	Update
Where this report has been discussed previously	Not applicable				

To your knowledge, does the report provide assurance or mitigate any significant risks? If yes, please detail which

Yes, The BAF Risk 2 around Urgent and Emergency Care, Cause: Demand overwhelms capacity and delays access to services; Event: Failure to meet national standards for timely urgent and elective care.

Impact assessment

- N/A

Acronyms used:

1. Purpose of the Report

- 1.1 To provide assurance to the Trust Board on the work of the Operations and Performance Committee and escalate any issues as required.

2. Recommendation

That the report be noted. (There are no items for approval).

3. Summary

The Operations and Performance Committee met on 26 July 2023. The meeting was quorate and considered the reports below.

4. Discussion Items

4.1 Cancer Quality and Performance Report (mitigating BAF Risk 2)

The Committee reviewed the performance for cancer care, noting that in May 2023 there had been improvements in four of the ten nationally reported standards, with the achievement of two of them; 2 Week Wait breast (symptomatic) and 31-day Subsequent Drugs. The data, yet to be validated, for June 2023 showed a deterioration in the performance for a number of standards, in part due to the cumulative effects of industrial action.

It was noted that there were improvement plans for each tumour site and significant progress had been made. However, service demand and industrial action were putting pressure on pathways.

The focus of the next few months would be reviewing theatre and oncology performance as the improvements for faster diagnostic shifted the pressure to these departments.

4.2 Briefing for Urgent and Emergency Care (mitigating BAF Risk 2)

The Committee received a briefing on developments in urgent and emergency care. It was reported that the performance for ambulance handovers had remained strong. Progress had been made in discharging patients Medically Optimised for Discharge. Challenges remained in relation to the 4-hour wait and 12-hour wait in Emergency Department. The Trust was an outlier with respect to the 12-hour wait and further detail would be reported in the following month.

The Cost Improvement Programme targets were noted. A piece of work would be undertaken by the System in August 2023 to assess capacity and demand.

4.3 Elective Care (RTT and DM01) (mitigating BAF Risk 2)

The Committee considered the latest position with respect to waiting times and actions to improve performance.

There were no patients waiting for treatment over 104-weeks as of mid-July. There were 73 patients waiting over 78 weeks, and industrial action had slowed the Trust getting to zero 78 week waiters. The trajectory for achieving zero 78-week waits was September 2023. The performance for 52 and 65 waits was on track.

As progress had been made with respect to those waiting longest, the focus would also include the overall waiting list. There was a need to understand why the number had increased recently, and to appropriately reduce follow up appointments through Patient Initiated Followed Up.

The performance for diagnostic services was moving in the right direction. Whilst endoscopy had been challenged the pressure had been alleviated by temporary provision. A new Unit would be built and open in October/November 2024.

5. Consideration of the BAF risks in the remit of Operations and Performance Committee

5.1 BAF Report

The Committee reviewed strategic risk 2 on the BAF around failure to meet national standards for timely urgent and elective care which was aligned to the Committee and its work plan. There were no changes to the risk assurance ratings or controls. The rating was 20 (likelihood of almost certain x impact of major); target rating 9; and tolerable rating is 15.

6. Any Other Business - None.

7. Reports for noting – the following items were received and noted, with no substantive discussion:

- Integrated Performance Report M3 2023/24